ALGS vs. ORKA, XERS, PROK, ALT, MNMD, STOK, RNAC, VERV, MLYS, and MGTX
Should you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Oruka Therapeutics (ORKA), Xeris Biopharma (XERS), ProKidney (PROK), Altimmune (ALT), Mind Medicine (MindMed) (MNMD), Stoke Therapeutics (STOK), Cartesian Therapeutics (RNAC), Verve Therapeutics (VERV), Mineralys Therapeutics (MLYS), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry.
Aligos Therapeutics vs.
Aligos Therapeutics (NASDAQ:ALGS) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, community ranking, risk and institutional ownership.
Oruka Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. Oruka Therapeutics' return on equity of -24.96% beat Aligos Therapeutics' return on equity.
Aligos Therapeutics has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 8.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Aligos Therapeutics received 14 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 65.85% of users gave Aligos Therapeutics an outperform vote.
Oruka Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oruka Therapeutics had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Oruka Therapeutics and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.79 beat Oruka Therapeutics' score of -0.25 indicating that Aligos Therapeutics is being referred to more favorably in the media.
Aligos Therapeutics currently has a consensus target price of $75.00, indicating a potential upside of 119.04%. Oruka Therapeutics has a consensus target price of $43.17, indicating a potential upside of 252.38%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Oruka Therapeutics is more favorable than Aligos Therapeutics.
Summary
Oruka Therapeutics beats Aligos Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Aligos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aligos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALGS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ALGS Stock Alerts